原发性肝癌 (prim ary hepatocellular carcinom a,PHC)是我国最常见的恶性肿瘤之一 ,预后较差 ,病死率逐年增高 ,是影响我国人民健康的重大疾病 [1 ] ,据卫生部统计我国每年约13万人死于肝癌 ,占全球肝癌死亡总数的 4 0 %。小肝癌切除仅使 10 %左右的患者受益 ,约 90 %的患者 Primordial hepatocellular carcinoma (PHC) is one of the most common malignant tumors in our country. Its prognosis is poor and mortality is increasing year by year. It is a major disease affecting the health of our people [1]. According to the Ministry of Health’s statistics, Approximately 130,000 people die of liver cancer, accounting for 40% of the global total. Small hepatocellular carcinoma resection benefits only about 10% of patients, about 90% of patients